RA Capital Backs Drug for Rare Kind of Chronic Pain

RA Capital backs drug for rare kind of chronic pain

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a medicine nearing pivotal testing.

Ambros Therapeutics, Ramaswamy’s latest startup, launches with plans for pain treatment

Vivek Ramaswamy may be in the midst of a neck-and-neck race for governor of Ohio, but he hasn’t left the world of biotech behind. Ramaswamy’s latest startup, Ambros Therapeutics, launched Tuesday with plans to develop a treatment for a rare form of the chronic pain condition Complex Regional Pain Syndrome. Ambros already has a drug candidate in hand — The company has licensed neridronate from the Italian pharmaceutical company Abiogen Pharma S.p…

Ambros Therapeutics Fast-Tracks Italian Non-Opioid Pain Drug Neridronate into US Trials

Ambros Therapeutics has launched with a significant $125 million Series A funding round, backed by RA Capital Management and Patient Square Capital’s platform Enavate Sciences, to bring a non-opioid pain medication to the U.S. market. The company has licensed neridronate, a bisphosphonate analgesic developed by Italy’s Abiogen Pharma and already approved in that country for conditions including chronic pain. With this substantial capital, Ambros…